%A Molica,Matteo %A Mazzone,Carla %A Niscola,Pasquale %A de Fabritiis,Paolo %D 2021 %J Frontiers in Oncology %C %F %G English %K Acute Myeloid Leukemia,TP53 mutations,Poor outcome,Decitabine (DAC),venetoclax (BCL-2 inhibitor) %Q %R 10.3389/fonc.2020.610820 %W %L %M %P %7 %8 2021-February-08 %9 Review %+ Matteo Molica,Haematology Unit, S. Eugenio Hospital, ASL Roma 2,Italy,molica@bce.uniroma1.it %# %! TP53 mutations in AML %* %< %T TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge? %U https://www.frontiersin.org/articles/10.3389/fonc.2020.610820 %V 10 %0 JOURNAL ARTICLE %@ 2234-943X %X TP53 is a key tumor suppressor gene with protean functions associated with preservation of genomic balance, including regulation of cellular senescence, apoptotic pathways, metabolism functions, and DNA repair. The vast majority of de novo acute myeloid leukemia (AML) present unaltered TP53 alleles. However, TP53 mutations are frequently detected in AML related to an increased genomic instability, such as therapy‐related (t-AML) or AML with myelodysplasia-related changes. Of note, TP53 mutations are associated with complex cytogenetic abnormalities, advanced age, chemoresistance, and poor outcomes. Recent breakthroughs in AML research and the development of targeted drugs directed at specific mutations have led to an explosion of novel treatments with different mechanisms. However, optimal treatment strategy for patients harboring TP53 mutations remains a critical area of unmet need. In this review, we focus on the incidence and clinical significance of TP53 mutations in de novo and t-AML. The influence of these alterations on response and clinical outcomes as well as the current and future therapeutic perspectives for this hardly treatable setting are discussed.